

Brussels, 9.12.2016
COM(2016) 785 final

ANNEX 1

ANNEX

to the

**REPORT FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT AND
THE COUNCIL**

**Report on the application of Regulation (EU) 2016/793 of the European Parliament and
of the Council of 11 May 2016 to avoid trade diversion into the European Union of
certain key medicines**

ANNEX

ViiV Healthcare/GSK packs sold in 2014 under Regulation (EU) 2016/793 (in-country sales data)

Product	Country destinations	Volume	Avg. selling price (\$)*
Combivir 300/150mg x 60	China, Kenya, Nigeria, Tanzania, Uganda	10,716	26.11
Epivir 150mg x 60	Azerbaijan, Indonesia, Kenya, Tanzania	14,299	10.60
Epivir Oral Solution 10mg/ml 240 ml	China, Honduras, Kenya	16,230	17.28
Retrovir 100mg x 100	Indonesia, Kenya	463	19.92
Retrovir Oral Solution 10mg/ml 200ml	Kenya	207	13.64
Ziagen 300mg x 60	Kenya	1,159	16.12
Retrovir 300mg x 60	no sales	no sales	no sales
Retrovir 250mg x 60	no sales	no sales	no sales
Trizivir 750mg	no sales	no sales	no sales

*includes distribution costs

ViiV Healthcare/GSK packs sold in 2015 under Regulation (EU) 2016/793 (in-country sales data)

Product	Country destinations	Volume	Avg. selling price (\$)*
Combivir 300/150mg x 60	China, Kenya, Nigeria, Tanzania, Uganda	8,839	25.84
Epivir 150mg x 60	China, Indonesia, Kenya, Moldova, Tanzania	9,778	13.56
Epivir Oral Solution 10mg/ml 240 ml	Honduras, Kenya, Moldova	541	21.69
Retrovir 100mg x 100	Indonesia, Kenya, Moldova	521	18.76
Retrovir Oral Solution 10mg/ml 200ml	China, Kenya, Moldova	17,609	14.75
Ziagen 300mg x 60	China, Kenya	49,701	17.85
Retrovir 300mg x 60	no sales	no sales	no sales
Retrovir 250mg x 60	no sales	no sales	no sales
Trizivir 750mg	no sales	no sales	no sales

*includes distribution costs